Aspira Women's Health Inc 8-K, filed Jun 29, 2020
Aspira Women's Health Inc. (AWHL)
About this 8-K
Aspira Women's Health Inc filed this 8-K on June 29, 2020.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2020
Aspira Women’s Health Inc.
(Exact name of registrant as specified in its charter)
| | | |
| --- | --- | --- | | Delaware | 001-34810 | 33-0595156 | | (State or other jurisdiction | (Commission | (IRS Employer | | of incorporation) | File Number) | Identification No.) | | | | --- | | 12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas | 78738 | | --- | --- | | (Address of principal executive offices) | (Zip Code) | Registrant’s telephone number, including area code: (512) 519-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | |
| --- | --- | | ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | --- | --- | | | | | --- | --- | | ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | | | | --- | --- | | ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | --- | --- | --- | | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.001 per share | AWH | The Nasdaq Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 23, 2020, the Company held the Annual Meeting. As of the close of business on the record date for the Annual Meeting, there were 97,377,890 shares of Company common stock issued and outstanding and entitled to vote. There were 86,112,253 shares present in person or by proxy at the Annual Meeting, constituting a quorum. The final voting results were as follows:
Proposal 1: Election of Directors
Stockholders elected each of the Company’s six nominees for director, as set forth below: | | | | | | --- | --- | --- | --- | | NOMINEE | FOR | WITHHOLD | BROKER NON-VOTES | | James S. Burns, D.L.S. | 65,012,071 | 680,910 | 20,419,272 | | Nancy G. Cocozza | 65,494,008 | 198,973 | 20,419,272 | | Veronica G.H. Jordan, Ph.D. | 65,477,674 | 215,307 | 20,419,272 | | James T. LaFrance | 65,546,386 | 146,595 | 20,419,272 | | Valerie B. Palmieri | 65,524,254 | 168,727 | 20,419,272 | | David R. Schreiber | 65,524,213 | 168,768 | 20,419,272 |
Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers
Stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2020, as set forth below: | | | | | | --- | --- | --- | --- | | FOR | AGAINST | ABSTENTIONS | BROKER NON-VOTES | | 65,218,736 | 421,911 | 52,334 | 20,419,272 |
Proposal 3: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm
Stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020, as set forth below:
| | | | | | --- | --- | --- | --- | | FOR | AGAINST | ABSTENTIONS | BROKER NON-VOTES | | 85,964,928 | 121,400 | 25,925 | 0 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Aspira Women’s Health Inc. | | --- | --- | --- | | | | Aspira Women’s Health Inc. | | | | | | Date: June 29, 2020 | By: | /s/ Robert Beechey | | | | Robert Beechey | | | | Chief Financial Officer |